Literature DB >> 28566340

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Lesley-Ann Sutton1,2, Anastasia Hadzidimitriou3, Panagiotis Baliakas1, Andreas Agathangelidis4, Anton W Langerak5, Stephan Stilgenbauer6, Sarka Pospisilova7, Zadie Davis8, Francesco Forconi9, Frederic Davi10, Paolo Ghia11, Richard Rosenquist1,2, Kostas Stamatopoulos1,3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28566340      PMCID： PMC5451327          DOI： 10.3324/haematol.2017.165605

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  24 in total

1.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

2.  ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia.

Authors:  P Ghia; K Stamatopoulos; C Belessi; C Moreno; S Stilgenbauer; F Stevenson; F Davi; R Rosenquist
Journal:  Leukemia       Date:  2007-01       Impact factor: 11.528

3.  Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases.

Authors:  A W Langerak; F Davi; P Ghia; A Hadzidimitriou; F Murray; K N Potter; R Rosenquist; K Stamatopoulos; C Belessi
Journal:  Leukemia       Date:  2011-04-01       Impact factor: 11.528

Review 4.  The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Semin Cancer Biol       Date:  2015-05-09       Impact factor: 15.707

5.  Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Authors:  Panagiotis Baliakas; Andreas Agathangelidis; Anastasia Hadzidimitriou; Lesley-Ann Sutton; Eva Minga; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao-Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles C Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin E Smedby; Lone Bredo Pedersen; Denis Moreno; Kirsten Van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie-Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian H Geisler; Anton W Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane F Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113

Review 6.  Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution.

Authors:  Anna Vardi; Andreas Agathangelidis; Lesley-Ann Sutton; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Cancer Res       Date:  2014-07-29       Impact factor: 12.701

Review 7.  BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.

Authors:  Adrian Wiestner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

8.  Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

Authors:  Gerard Tobin; Ulf Thunberg; Anna Johnson; Inger Eriksson; Ola Söderberg; Karin Karlsson; Mats Merup; Gunnar Juliusson; Juhani Vilpo; Gunilla Enblad; Christer Sundström; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

9.  Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Authors:  Lesley-Ann Sutton; Emma Young; Panagiotis Baliakas; Anastasia Hadzidimitriou; Theodoros Moysiadis; Karla Plevova; Davide Rossi; Jana Kminkova; Evangelia Stalika; Lone Bredo Pedersen; Jitka Malcikova; Andreas Agathangelidis; Zadie Davis; Larry Mansouri; Lydia Scarfò; Myriam Boudjoghra; Alba Navarro; Alice F Muggen; Xiao-Jie Yan; Florence Nguyen-Khac; Marta Larrayoz; Panagiotis Panagiotidis; Nicholas Chiorazzi; Carsten Utoft Niemann; Chrysoula Belessi; Elias Campo; Jonathan C Strefford; Anton W Langerak; David Oscier; Gianluca Gaidano; Sarka Pospisilova; Frederic Davi; Paolo Ghia; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

10.  An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.

Authors: 
Journal:  Lancet Oncol       Date:  2016-05-13       Impact factor: 41.316
View more
  10 in total

1.  p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.

Authors:  Richard Rosenquist
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

2.  Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.

Authors:  Christian Brieghel; Savvas Kinalis; Christina W Yde; Ane Y Schmidt; Lars Jønson; Michael A Andersen; Caspar da Cunha-Bang; Lone B Pedersen; Christian H Geisler; Finn C Nielsen; Carsten U Niemann
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

3.  Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Authors:  Jitka Malcikova; Sarka Pavlova; Barbara Kunt Vonkova; Lenka Radova; Karla Plevova; Jana Kotaskova; Karol Pal; Barbara Dvorackova; Marcela Zenatova; Jakub Hynst; Eva Ondrouskova; Anna Panovska; Yvona Brychtova; Kristyna Zavacka; Boris Tichy; Nikola Tom; Jiri Mayer; Michael Doubek; Sarka Pospisilova
Journal:  Blood       Date:  2021-12-23       Impact factor: 25.476

Review 4.  Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases.

Authors:  Thierry Soussi; Panagiotis Baliakas
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

Review 5.  Impact of Low-Burden TP53 Mutations in the Management of CLL.

Authors:  Gregory Lazarian; Florence Cymbalista; Fanny Baran-Marszak
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 6.  Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.

Authors:  Andreas Agathangelidis; Anastasia Chatzidimitriou; Thomas Chatzikonstantinou; Cristina Tresoldi; Zadie Davis; Véronique Giudicelli; Sofia Kossida; Chrysoula Belessi; Richard Rosenquist; Paolo Ghia; Anton W Langerak; Frédéric Davi; Kostas Stamatopoulos
Journal:  Leukemia       Date:  2022-05-25       Impact factor: 12.883

7.  Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia.

Authors:  Emily D Rout; Robert C Burnett; Julia D Labadie; Janna A Yoshimoto; Anne C Avery
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

Review 8.  B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.

Authors:  Katerina Gemenetzi; Andreas Agathangelidis; Laura Zaragoza-Infante; Electra Sofou; Maria Papaioannou; Anastasia Chatzidimitriou; Kostas Stamatopoulos
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

9.  Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.

Authors:  Paola Monti; Marta Lionetti; Giuseppa De Luca; Paola Menichini; Anna Grazia Recchia; Serena Matis; Monica Colombo; Sonia Fabris; Andrea Speciale; Marzia Barbieri; Massimo Gentile; Simonetta Zupo; Mariella Dono; Adalberto Ibatici; Antonino Neri; Manlio Ferrarini; Franco Fais; Gilberto Fronza; Giovanna Cutrona; Fortunato Morabito
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

10.  Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay.

Authors:  Selena Mimmi; Domenico Maisano; Vincenzo Dattilo; Massimo Gentile; Federico Chiurazzi; Alessandro D'Ambrosio; Annamaria Zimbo; Nancy Nisticò; Annamaria Aloisio; Eleonora Vecchio; Giuseppe Fiume; Enrico Iaccino; Ileana Quinto
Journal:  Biomedicines       Date:  2022-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.